Brookline Capital Markets Comments on CADL Q2 Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL) – Research analysts at Brookline Capital Markets issued their Q2 2026 earnings estimates for Candel Therapeutics in a research note issued to investors on Sunday, May 17th. Brookline Capital Markets analyst K. Dolliver forecasts that the company will post earnings per share of ($0.26) for the quarter. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($0.88) per share. Brookline Capital Markets also issued estimates for Candel Therapeutics’ Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.31) EPS and FY2026 earnings at ($1.11) EPS.

Candel Therapeutics (NASDAQ:CADL) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.16.

CADL has been the topic of a number of other reports. Zacks Research raised shares of Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Monday, April 20th. Citigroup decreased their target price on shares of Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research note on Friday, March 13th. Cantor Fitzgerald began coverage on shares of Candel Therapeutics in a research note on Monday, April 20th. They issued an “overweight” rating on the stock. Finally, Wall Street Zen upgraded shares of Candel Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Candel Therapeutics Price Performance

CADL stock opened at $7.66 on Wednesday. The firm has a 50 day moving average of $6.03 and a 200-day moving average of $5.65. The company has a current ratio of 28.05, a quick ratio of 28.05 and a debt-to-equity ratio of 0.34. Candel Therapeutics has a 12 month low of $4.35 and a 12 month high of $9.27. The firm has a market capitalization of $561.25 million, a P/E ratio of -7.82 and a beta of -0.59.

Insider Activity at Candel Therapeutics

In other Candel Therapeutics news, Director Paul B. Manning purchased 550,458 shares of Candel Therapeutics stock in a transaction dated Monday, February 23rd. The stock was purchased at an average price of $5.45 per share, with a total value of $2,999,996.10. Following the transaction, the director directly owned 2,763,527 shares of the company’s stock, valued at $15,061,222.15. This trade represents a 24.87% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 14.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Candel Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets grew its stake in shares of Candel Therapeutics by 128.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock valued at $40,000 after acquiring an additional 4,439 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in shares of Candel Therapeutics in the 4th quarter worth about $51,000. Tower Research Capital LLC TRC increased its stake in Candel Therapeutics by 361.7% during the second quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock worth $49,000 after acquiring an additional 7,527 shares during the last quarter. Invesco Ltd. bought a new position in shares of Candel Therapeutics during the 1st quarter valued at approximately $59,000. Finally, ProShare Advisors LLC bought a new stake in Candel Therapeutics in the fourth quarter worth $59,000. Hedge funds and other institutional investors own 13.93% of the company’s stock.

Candel Therapeutics News Roundup

Here are the key news stories impacting Candel Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its 2026 EPS estimates for Candel Therapeutics, trimming expected losses for the year to ($0.85) from ($1.03), and also improved forecasts for Q2, Q3, and Q4 2026. HC Wainwright estimate update
• Positive Sentiment: The same firm also boosted longer-term estimates for FY2027 to $0.35 per share, signaling a more bullish outlook for profitability later in the pipeline. HC Wainwright long-term estimate update
• Positive Sentiment: Brookline Capital Markets also published estimates that were broadly constructive, with FY2026 EPS projected at ($1.11) and quarterly losses narrowing into year-end. Brookline Capital Markets estimate update
• Neutral Sentiment: A Zacks note highlighted that analysts’ mean price target implies roughly 148.5% upside, which may be reinforcing speculative interest in the stock. Zacks article on analyst upside

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.